The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Measuring Alpha-Synuclein in Extracellular Vesicles, 2024Measuring Alpha-synuclein in Extracellular Vesicles: A Biomarker for the Diagnosis and Staging of Neuronal α-Synuclein Diseases
Study Rationale: Parkinson's disease (PD) and dementia with Lewy bodies involve accumulation of alpha-synuclein in neurons. A recently developed test for alpha-synuclein aggregates in cerebrospinal...
-
ASAP CRN Competitive Renewal Opportunity, 2024Examining the Mechanisms of Mitochondrial Damage Control by PINK1 and Parkin
Study Rationale: Mutations in PINK1 and Parkin genes underlie some forms of Parkinson’s disease (PD). The protein products of these genes are responsible for the maintenance and degradation of...
-
ASAP CRN Competitive Renewal Opportunity, 2024Studying Basal Ganglia Networks in Parkinson's Disease
Study Rationale: People with Parkinson's disease (PD) have long been known to display remarkable motor abilities under special circumstances, such as situations that involve strong emotions or stress...
-
ASAP CRN Competitive Renewal Opportunity, 2024Determining the Role of Proteins Associated with Parkinson’s Disease in T cell-Mediated Destruction of Dopamine Neurons
Study Rationale: Before Parkinson's disease (PD) manifests its characteristic symptoms, the pathological process has been underway for years. Although the initial trigger remains uncertain, we have...
-
ASAP CRN Competitive Renewal Opportunity, 2024Circuit Mechanisms for Dopamine Neuron Vulnerability and Resilience in Parkinson’s Disease
Study Rationale: Dopamine neurons are particularly vulnerable to death in Parkinson’s disease (PD), and their loss is one of the main causes of movement problems in people with PD. Dopamine neurons...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2024A Novel Approach to Activating Glucosylceramidase in People with Parkinson’s Disease
Study Rationale: Genetic mutations resulting in a depletion of glucosylceramidase activity is the most predisposing risk factor for developing Parkinson’s disease (PD). Activating glucosylceramidase...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.